Top news of the week: 03.03.2020.
#CFdad #RareDisease #patients #RareDiseaseDay #XconBioRoundup #Biotech #Pharma
Startups
MPM gains first offer on Dana-Farber tech, raises $100M fund https://t.co/JqLnZbcPTe https://t.co/Vo9ztilaAF
OpenMPM gains first refusal on Dana-Farber tech, raises $100M fund
MPM Capital and Dana-Farber Cancer Institute have formed a venture philanthropy alliance, raising a $100 million investment fund and $26 million in donations to support early stage research.
Waksal's bid for Redx ends, forcing biotech to avert cash crunch https://t.co/ON9iJ0lyFJ https://t.co/QE0w0eWyPl
OpenWaksal's bid for Redx ends, forcing biotech to avert cash crunch
Sam Waksal’s attempt to buy Redx Pharma has fallen apart. The failure of a company set up by the once-jailed biotech executive to close a deal led Redx to turn to Redmile for the cash to ...
Nouscom interim CEO becomes full-time as Amal exec becomes CMO
Nouscom has finally got its permanent CEO as it also nabs a new chief medical officer out of Amal Therapeutics.
Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More
Clinical trials have historically hewn to a rigid format. A trial is designed, conducted according to that design, and then results are analyzed. Making
Moderna wins bragging rights as it kick-starts first experimental coronavirus clinical trial https://t.co/TTJXKoEH8M
OpenModerna wins bragging rights as it kick-starts first experimental coronavirus clinical trial
Moderna shares shot up a massive 18% after-hours last night on the fairly standard news that it was about to start a drug trial.
RT @MassBio: In honor of #RareDiseaseDay, MassBio President & CEO @BobCoughlin discusses his journey as a #CFdad, the path to "buying a cure" & the work ahead to find a treatment for the millions of #RareDisease #patients still waiting. Read more via @MediaplanetUSA https://t.co/ruTctR4bCs
OpenThe Path to a Cure: Finding Hope in a World of Rare Diseases
For rare disease patients, the path to a cure used to be a race against the clock. Today, we celebrate the progress that is saving lives.
BioPharma M&A Drives More Efficient Resource Allocation - of talent, science, and capital. Policymakers need to appreciate the broader benefits of industry M&A. #Biotech #Pharma https://t.co/TZ6qRCOnY0 https://t.co/ziJQAWd9rv
OpenBioPharma M&A Drives More Efficient Resource Allocation
M&A is an omnipresent reality in the biopharma industry, from Big Pharma mega-mergers to smaller acquisitions of emerging startups. We’ve recently witnessed several large M&A transactions ...
MPM Capital Raises $100 Million Fund, Teams Up With Dana-Farber Cancer Institute
Through the partnership, MPM raised the new MPM Oncology Innovations Fund LP and Dana-Farber secured $26 million in donations for its cancer-research pool.